Eduardo Yepez Guevara, M.D., FACP, FIDSA
Department of Infectious Diseases, Infection Control, and Employee Health, Division of Internal Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Infectious Diseases, Infection Control and Employee Health, Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Fellowship Program Associate Director, Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2006 | Universidad Nacional de Trujillo, Trujillo, PE, Medicine, MD |
Postgraduate Training
| 2018-2019 | Clinical Fellowship, Transplantation Infectious Diseases, The University of Texas Health Science Center at Houston, Houston, Texas |
| 2016-2018 | Clinical Fellowship, Infectious Diseases, The University of Texas Health Science Center at Houston, Houston, Texas |
| 2011-2013 | Clinical Residency, Internal Medicine, New York Medical College - Metropolitan Hospital, New York, New York |
| 2010-2011 | Clinical Internship, Internal Medicine, New York Medical College - Metropolitan Hospital, New York, New York |
| 2008-2010 | House Physician in Clinical Immunology, University of Miami - Jackson Memorial Hospital, Miami, Florida |
Licenses & Certifications
| 2026 | Certificate of Clinical Educator Excellence |
| 2026 | American Heart Association Basic Life Support |
| 2023 | Mississippi State Board of Medical Licensure |
| 2023 | Georgia Composite Medical Board |
| 2023 | Tennessee Board of Medical Examiners |
| 2023 | Oklahoma State Board of Medical Licensure |
| 2023 | Washington State Department of Health |
| 2023 | Arizona Board of Medical Examiners |
| 2023 | Alabama Board of Medical Examiners |
| 2023 | Louisiana State Board of Medical Examiners |
| 2021 | Florida Board of Medicine |
| 2018 | American Board of Internal Medicine - Infectious Disease |
| 2013 | American Board of Internal Medicine - Internal Medicine, enrolled in Longitudinal Knowledge Assessment |
| 2013 | Medicine, New York |
| 2012 | Physician Full Permit, Texas |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Infectious Diseases, Infection Control and Employee Health, Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2019 - 2025
Assistant Professor, General Internal Medicine, New York Medical College - Metropolitan Hospital, New York, New York, 2013 - 2016
Administrative Appointments/Responsibilities
Vice Chair DoIM Education Committee, Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2025 - Present
Faculty Senator, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - 2025
Associate Program Director, Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2022 - Present
Associate Program Director, Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2022 - Present
Core Faculty- Infectious Diseases Fellowship, Infectious Diseases, Baylor College of Medicine, Houston, Texas, 2022 - Present
Core Faculty- Infectious Diseases Fellowship, Infectious Diseases, The University of Texas Health Science Center at Houston, Houston, Texas, 2022 - Present
EPIC Super User, Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2021 - Present
Associate Medical Director, Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2020 - Present
Chief Clinical Fellow in Infectious Diseases, Infectious Diseases, The University of Texas Health Science Center at Houston, Houston, Texas, 2017 - 2018
Assistant Chief Medical Resident, General Internal Medicine, New York Medical College - Metropolitan Hospital, New York, New York, 2012 - 2013
Other Professional Positions
MD Anderson Cancer Network Peer-to-Peer Program - Immuno-Oncology Toxicity (IOTOX) Consultant, Infectious Diseases, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2025 - Present
Cooperative Service - Texas Viral Hepatitis Elimination Summit, Infectious Diseases, Texas Department of State Health Services, Houston, Texas, 2023
Consultant / Panelist - Infections in the Hematopoietic Cell Transplantation Setting: Improving Outcomes Through Interdisciplinary Care (Web Based CME Activity), Terranova Medica and Society of Infectious Diseases Pharmacists Education Center (SIDPEC), 2020 - 2021
Intramural Institutional Committee Activities
Vice Chair, DoIM Education Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
FY25 Excellence in Education Awards Reviewer, Department of Internal Medicine Education Committee, The University of Texas MD Anderson Cancer Center, 2025 - 2025
Lead for the Educate the Educator working group, Division of Internal Medicine Education Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Graduate Medical Education Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Pharmacy & Therapeutics Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Associate Medical Director, Antimicrobial Stewardship Team, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, Clinical Competence Committee, New York Medical College - Metropolitan Hospital, 2013 - 2016
Extramural Institutional Committee Activities
Trainee Lead, Hepatitis C Special Interest Group AASLD, American Association for the Study of Liver Diseases, 2025 - 2026
Member, International ECHO Sessions on Viral Hepatitis in Patients with Cancer, The University of Texas MD Anderson Cancer Center, 2023 - Present
Honors & Awards
| 2026 - Present | Clinical Educator Excellence, The University of Texas MD Anderson Cancer Center |
| 2026 - Present | Nominee MD Anderson Excellence Award Patient Care, Md Anderson Cancer Center |
| 2026 - Present | Nominee MD Anderson Excellence Award Quality, MD Anderson Cancer Center |
| 2026 - Present | Fellow of the Infectious Diseases Society of America, Infectious Diseases Society of America |
| 2026 - 2029 | Multi-Year Appointment Award - Clinical Faculty Appointment track, The University of Texas MD Anderson Cancer Center |
| 2026 | Awesome Job, Md Anderson |
| 2025 | Clinical Safety & Effectiveness (CS&E), MD Anderson Cancer Center- Clinical Safety & Effectiveness and Reliability |
| 2025 | Applying Lean Concepts to Healthcare Processes - Introductory Level, MD Anderson Cancer Center - Office of Performance Improvement |
| 2025 | DOIM Educator of the Quarter, The University of Texas MD Anderson Cancer Center |
| 2024 | Awesome Job Award, MD Anderson Infectious Diseases APPs |
| 2024 | Serious Illness Conversation Guide Training for Physicians and APPs, MD Anderson Cancer Center |
| 2023 | Fellow of the American College of Physicians, American College of Physicians |
| 2019 | Second Place Clinical Research - Poster Session Award, Division of Internal Medicine Research Retreat - MD Anderson Cancer Center |
| 2018 | Fellow Scholarship Award, Remington Winter Course in Infectious Diseases |
| 2017 | Trainee Travel Grant Award, Infectious Diseases Society of America |
| 2014 | Most Outstanding Clinical Preceptor, New York Medical College - Metropolitan Hospital |
| 2011 | Most Outstanding PGY1, New York Medical College - Metropolitan Hospital |
| 2010 | House Physician Award, University of Miami - Jackson Memorial Hospital |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. Bridging the communication gap between consultative and primary services. Conference. FY26 Internal Medicine and Cancer Survivorship Grand Rounds. Houston, Texas, US.
- 2022. Update on COVID-19 management and treatment. Invited. Clinical Conference - Leukemia Clinical Service. Houston, Texas, US.
International Presentations
- 2026. Liver Injury in a Multiply Relapsed ALL Patient. Invited. MD Anderson International Virtual Sessions on Management of Viral Hepatitis in Patients with Cancer - Extension for Community Healthcare Outcomes (ECHO) Project. Houston, US.
- 2025. Acute Hepatitis due to Disseminated Adenovirus Infection. Invited. MD Anderson International Virtual Sessions on Management of Viral Hepatitis in Patients with Cancer - Extension for Community Healthcare Outcomes (ECHO) Project. Houston, US.
- 2025. Management of chronic hepatitis B in a patient with cancer and prior history of reactivation. Invited. MD Anderson International Virtual Sessions on Management of Viral Hepatitis in Patients with Cancer - Extension for Community Healthcare Outcomes (ECHO) Project, US.
- 2024. Acute viral hepatitis reactivation - Challenging case. Invited. MD Anderson International Virtual Sessions on Management of Viral Hepatitis in Patients with Cancer - Extension for Community Healthcare Outcomes (ECHO) Project. Houston, US.
- 2022. COVID-19 update and treatment of Immunocompromised patients. Invited. Management of COVID19: Advances and Perspectives. Mexico, MX.
- 2019. Clinical outcomes, bacterial loads, and markers of intestinal inflammation in immunocompromised and cancer patients with diarrhea and Clostridioides difficile identified by nucleic acid amplification tests (NAAT) and toxin A/B by enzyme immunoassay (EIA). Poster. European Society of Clinical Microbiology and Infectious Diseases Global 2019. Amsterdam, NL.
Selected Publications
Peer-Reviewed Articles
- Angelides PK, Salamo O, Cherian SV, Eduardo Yepez Guevara, Jimenez CA, Faiz SA. A 65-year-old man with cough, hypercalcemia, and diffuse opacities. Radiol Case Rep 20(8):3836-3839, 2025. e-Pub 2025. PMID: 40486148.
- Torres HA, Mustafayev K, Juneau R, Hwang JP, Wang LS, Angelidakis G, Hawk E, Granwehr BP, Yepez Guevara E, Ying AK. Implementation of Universal Hepatitis C Virus Screening in a Tertiary Care Cancer Center. JNCCN 22(2D), 2024. e-Pub 2024. PMID: 38729204.
- Alexander Franklin, Teny M John, Fareed Khawaja, Ying Jiang, Yepez Guevara E, Jitesh Ahuja, Saadia A Faiz, Lara Bashoura, Ajay Sheshadri, Vickie R Shannon, Diwakar D Balachandran, Kelly McConn, Victor E Mulanovich, Micah Bhatti, Roy F Chemaly. Utility of Bronchoalveolar Lavage for the Diagnosis and Management of COVID-19 in Patients With Cancer. J Infect Dis, 2023. e-Pub 2023. PMID: 37983000.
- Yibirin M, Mustafayev K, Hosry J, Pundhir P, Klingen J, Yepez Guevara E, Granwehr BP, Kaseb A, Naing A, Patel S, Shah AY, Skoulidis F, Tawbi HA, Wang L, Miller E, Zhang HC, Zurita-Saavedra A, Torres HA. Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients with Solid Tumors. Am J Gastroenterol 118(9):1609-1617, 2023. e-Pub 2023. PMID: 37307533.
- Dagher H, Chaftari AM, Subbiah IM, Malek AE, Jiang Y, Lamie P, Granwehr B, John T, Yepez E, Borjan J, Reyes-Gibby C, Flores M, Khawaja F, Pande M, Ali N, Rojo R, Karp DD, Chaftari P, Hachem R, Raad II. Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period. Elife 12, 2023. e-Pub 2023. PMID: 36748905.
- Raad, II, Hachem, RY, Masayuki, N, Datoguia, TS, Dagher, H, Jiang, Y, Subbiah, V, Siddiqui, B, Bayle, A, Somer, RA, Fernández-Cruz, A, Gorak, E, Bhinder, A, Mori, N, Hamerschlak, N, Shelanski, S, Dragivich, T, Kiat, YV, Fakhreddine, S, Hanna, PA, Chemaly, RF, Mulanovich, VE, Adachi, JA, Borjan, J, Khawaja, F, Granwehr, BP, John, TM, Yepez Guevara, E, Torres, HA, Ammakkanavar, NR, Yibirin, M, Reyes-Gibby, CC, Pande, M, Ali, N, Rojo, RD, Ali, S, Deeba, R, Chaftari, P, Matsuo, T, Ishikawa, K, Hasegawa, R, Aguado-Noya, R, García, ÁG, Puchol, CT, Lee, DG, Slavin, MA, Teh, B, Arias, CA, Kontoyiannis, DP, Chaftari, AP. International Multicenter Study Comparing COVID-19 in Patients With Cancer to Patients Without Cancer: impact of Risk Factors and Treatment Modalities on Survivorship. ELife 12, 2023. e-Pub 2023. PMID: 36715684.
- Ariel D Szvalb MD, Eduardo Yepez Guevara MD, Elizabeth Euscher MD, MD PhD KAN, Dimitrios P Kontoyiannis MD. Acute Peritoneal Histoplasmosis Mimicking Ovarian Cancer and Review of the Literature on Histoplasma Peritonitis. Open Forum Infectious Diseases 10(1), 2023. e-Pub 2023. PMID: 36686636.
- Francisco, D, Zhang, L, Jiang, Y, Olvera, AV, Adachi, JA, Yepez Guevara, E, Aitken, SL, Garey, K, Peterson, CB, Do, K, Dillon, R, Obi, EN, Jenq, RR, Okhuysen, PC. Risk Factors Associated with Severe Clostridioides difficile Infection in Patients with Cancer. Infectious Diseases and Therapy 12(1):209-225, 2023. e-Pub 2023. PMID: 36443547.
- Yibirin M, Hosry J, Yepez Guevara E, Granwehr BP, Jiang Y, Mustafayev K, Angelidakis G, Torres HA. High sustained virologic response rate after 8 weeks of direct-acting antivirals in cancer patients with chronic hepatitis C virus. Eur J Gastroenterol Hepatol 34(10):1098-1101, 2022. e-Pub 2022. PMID: 36062500.
- Yepez Guevara EA, Aitken SL, Olvera AV, Carlin L, Fernandes KE, Bhatti MM, Garey KW, Adachi J, Okhuysen PC. Clostridioides difficile infection in cancer and immunocompromised patients: Relevance of a two-step diagnostic algorithm and infecting ribotypes on clinical outcomes. Clin Infect Dis 72(10):e460-e465, 2021. e-Pub 2021. PMID: 32803229.
- Mohammed Samannodi, Vaghefi-Hosseini R, Nigo M, Guevara EY, Hasbun R. Risk Classification for Respiratory Viral Infections in Adult Solid Organ Transplantation Recipients. Transplantation Proceedings 53(2):737-742, 2020. e-Pub 2020. PMID: 33272649.
- Galarreta CI, Yepez E, Velez C, Aita G. [Primary T cell lymphoma of the pancreas: clinical case report]. Rev Gastroenterol Peru 32(4):423-8, 2012. e-Pub 2012. PMID: 23307095.
Professional Educational Materials
- Yepez Guevara E, MD, Carolyn Wester, MD, Ponni Perumalswami, MD, Philip Vutien, MD, Harrys Torres, MD. New Diagnostics and Guidelines Developments Advancing Hepatitis C Elimination in the United States. AASLD, 2025.
- Carolyn Alonso, Vasilios Athans, Dayna McManus, Jennifer L. Saullo, Frank Tverdek, Yepez Guevara E. Infections in the Hematopoietic Cell Transplantation Setting: Improving Outcomes Through Interdisciplinary Care - Web CME Activity. Terranova Medica and Society of Infectious Diseases Pharmacists Education Center (SIDPEC), 2020.
Abstracts
- Torres HA, Haymaker C, Mustafayev K, Arvelaez Pascucci J, Rashid A, Elsayes KM, Qiao W, Arrechedera C, Solis Soto L, Amador-Molina JC, Yepez Guevara E, Kaseb AO. Improving immunotherapy response with direct-acting antiviral therapy in patients with advanced hepatocellular carcinoma and chronic hepatitis C virus infection. 2026 ASCO Annual Meeting, 2026. e-Pub 2026.
- Mustafayev K, Jiang Y, Yepez Guevara E, Torres HA. Risk of Hepatitis B Virus Reactivation in Patients with Rheumatoid Arthritis Treated with Janus Kinase Inhibitors: A Meta-Analysis. International Immunocompromised Host Society (ICHS) 24th Biennial Symposium, 2026. e-Pub 2026.
- Arvelaez Pascucci J, Mustafayev K, Jain P, Jiang Y, Yepez Guevara E, Torres HA. Hepatitis C virus reactivation in cancer patients receiving Bruton tyrosine kinase inhibitors. ESCMID Global 2026, 2026. e-Pub 2026.
- Mustafayev K, Arvelaez J, Naing A, Thomas SK, Patel KK, Pemmaraju V, Daver NG, Jiang Y, Yepez Guevara E, Torres HA. The Use of Direct-Acting Antivirals to Enhance Access to Cancer Clinical Trials for Patients with Chronic Hepatitis C Virus Infection and Cancer. AASLD The Liver Meeting® 2025, 2025. e-Pub 2025.
- Joanne Arvelaez, Khalis Mustafayev, Ying Jiang, Yepez Guevara E, Harrys A. Torres. Clinical Significance of Indeterminate Hepatitis C Antibody Results in Cancer Patients. ID Week 2025, 2025. e-Pub 2025.
- Torres HA, Mustafayev K, Chiu CY, Ozaras R, Yemisen M, Portillo D, Holguin A, Egge S, Puoti M, Francisco D, Portugal Gonzales J, King GE, Mouliade C, Anolli MP, Lampertico P, Mallet V, Arvelaez Pascucci J, Yepez Guevara E. International Virtual Sessions on Management of Viral Hepatitis in Patients with Cancer. The Global Hepatitis Summit 2025, 2025. e-Pub 2025.
- Khalis Mustafayev, Yepez Guevara E, Naveen Pemmaraju, Elias Jabbour, Issa Ghayas, Courtney Dinardo, Ratan Ravin, Harrys Torres. Virologic effect of BCR-ABL tyrosine kinase inhibitors in cancer patients with chronic hepatitis C virus infection: A prospective study. AASLD The Liver Meeting 2024, 2024. e-Pub 2024. PMID: 39368210.
- Torres HA, Mustafayev K, Juneau R, Hwang JP, Wang LS, Angelidakis G, Granwehr BP, Yepez Guevara E, Ying AK. Implementation of Universal Hepatitis C Virus Screening in a Tertiary Care Cancer Center. AASLD The Liver Meeting 2023, 2023. e-Pub 2023.
- Mustafayev K, Naing A, Thomas SK, Patel KK, Pemmaraju N, Daver NG, Jiang Y, Yepez Guevara E, Torres HA. Treatment of Chronic Hepatitis C Virus Infection To Increase Access To Cancer Clinical Trials In Patients With Hematologic Malignancies: A Prospective Observational Study. Journal of Clinical Oncology 41(16):3142-3142, 2023. e-Pub 2023.
- Chiu CY, Mustafayev K, Lee HC, Manasanch EE, Yepez Guevara E, Samaniego F, Torres HA. Effect of anti-CD38 monoclonal antibodies on hepatitis C virus replication in chronically infected patients with multiple myeloma: A prospective series. 18th Global Hepatitis Summit, 2023. e-Pub 2023.
- Franklin A, John T, Jiang Y, Yepez E, McConn K, Khawaja F, Bhatti M, Chemaly R. Discordant COVID-19 PCR results from nasopharyngeal swab and bronchoalveolar lavage at a major cancer center. European Society of Clinical Microbiology and Infectious Diseases Global Meeting, 2022. e-Pub 2022.
- Yibirin M, Pundhir P, Yepez Guevara E, Granwehr BP, Kaseb A, Patel S, Naing A, Shah AY, Skoulidis F, Tawbi HA, Zhang HC, Wang L, Miller E, Torres HA. SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN CANCER PATIENTS WITH CHRONIC HEPATITIS C INFECTION: A PROSPECTIVE OBSERVATIONAL STUDY. AASLD The Liver Meeting 2020, 2020. e-Pub 2020.
- Yibirin M, Yepez Guevara E, Granwehr BP, Pundhir P, Torres HA. Short duration of Direct Acting Antivirals in cancer patients with chronic hepatitis C virus infection. AASLD The Liver Meeting 2020, 2020. e-Pub 2020.
- Francisco D, Olvera A, Jiang Y, Zhang L, Guevara EY, Garey KW, Peterson C, Kim-Anh, Dillon R, Obi EN, Jenq R, Okhuysen PC. Metronidazole Exposure Prior to Clostridiodes difficile Infection (CDI) is a Risk Factor for Severe C. difficile Disease in Cancer Patients. Open Forum Infect Dis, 2020. e-Pub 2020.
- Francisco DM, Olvera A, Zhang L, Yepez Guevara E, Garey K, Peterson C, Do K, Dillon R, Jenq R, Okhuysen P. Fecal Collinsella Abundance is Negatively Associated with Toxin A/B Production in Cancer Patients with Clostridioides difficile. Open Forum Infect Dis 6(Suppl 2):S821–S822, 2019. e-Pub 2019.
- Olvera A, Yepez Guevara E, Garey K, Dillon R, Okhuysen P. Fecal Biomarkers for Clostridioides difficile Infection in Cancer Patients. Open Forum Infectious Diseases 6(Suppl 2):S763-S764, 2019. e-Pub 2019.
- Eduardo YG, Aitken S, Carlin L, Fernandes K, Bhatti M, Garey K, Adachi J, Okhuysen P. Clinical outcomes, bacterial loads, and markers of intestinal inflammation in immunocompromised and cancer patients with diarrhea and Clostridioides difficile identified by nucleic acid amplification tests (NAAT) and toxin A/B by enzyme immunoassay (EIA). European Society of Clinical Microbiology and Infectious Diseases Global Meeting, 2019. e-Pub 2019.
- Eduardo YG, Harika Y, Andrew C, Kevin G, Micah B, Samuel A, Pablo O. Relevance of Clostridium difficile ribotype 014-20 in cancer patients with diarrhea. European Society of Clinical Microbiology and Infectious Diseases Global Meeting, 2018. e-Pub 2018.
- Andrew C, Harika Y, Eduardo YG, Micah B, Samuel A, Pablo O. Line of Service – Specific Performance and Antibiotic Prescribing Habits Following Introduction of a Two-Step Diagnostic Approach Using NAAT Followed by Enzyme Immunoassay in Cancer Patients with Suspected Clostridium difficile Infection. Open Forum Infectious Diseases 4(Suppl 1):S394, 2017. e-Pub 2017.
- Yepez E, Yalamanchili H, Chao A, Garey K, Bhatti M, Aitken S, Okhuysen P. Ribotypes matter. Significance of Clostridium difficile ribotypes in Cancer patients with diarrhea. Open Forum Infectious Diseases 4(Suppl 1):S386–S387, 2017. e-Pub 2017.
- Harika Y, Andrew C, Eduardo YG, Samuel A, Micah B, Pablo O. Risk Factors and Clinical Outcomes of Cancer Patients with Clostridium difficile Associated Diarrhea Co-infected with a Second Enteropathogen. Open Forum Infect Dis 4(Suppl 1):S362–S363, 2017. e-Pub 2017.
- Torres HA, Mustafayev K, Granwehr BP, Feldman AR, Spallone A, Yepez Guevara E. Infection Control Approach to Hepatitis C Virus Screening at a Tertiary Care Cancer Center in the United States. The Liver Meeting 2026.
- Mustafayev K, Patel KK, Gotimukul A, Gaballa MM, Thomas SK, Mulanovich V, Ariza-Heredia EJ, Okhuysen PC, Yepez Guevara E, Khawaja F, Torres HA. Hepatitis B Virus Reactivation in Patients with Cancer Receiving Bispecific T-cell Engager Therapy. ID Week 2026.
Book Chapters
- Yepez Guevara, E, Abdel Rahman, Z, Daher, M, Mulanovich, VE. Management of Infections in Stem Cell Transplant Recipients. In: Manual of Stem Cell Transplantation and Cellular Therapies for Hematologic Malignancies. ELSEVIER, 429-442, 2023.
- Yepez E, Banchs J, Tweardy D, Adachi J. Infectious Endocarditis in Cancer patients. In: Cancer and the Heart. 3. People’s Medical Publishing House, 477-489, 2019.
Letters to the Editor
- Mustafayev K, Yepez Guevara E, DiNardo CD, Jabbour E, Ghayas IC, Ratan R, Pemmaraju N, Torres HA. Virologic effect and hepatotoxicity of BCR:ABL1 tyrosine kinase inhibitors in cancer patients with chronic hepatitis C virus infection: A prospective study. Leuk Res 147: 107597, 2024.
- Chiu, CY, Mustafayev, K, Lee, HC, Manasanch, EE, Yepez Guevara, E, Torres, HA. Effect of anti-CD38 monoclonal antibodies on hepatitis C virus replication in chronically infected patients with multiple myeloma a prospective series. Leukemia and Lymphoma 64: 900-903, 2023.
- Pundhir, P, Roach, LR, Bartek, J, Trask, RP, Yibirin, M, Yepez Guevara, E, Granwehr, BP, Swalwell, CR, Torres, HA. Nursing practice is associated with high risk for hepatitis C virus infection. Clinical Microbiology and Infection 27: 1362-1364, 2021.
Patient Reviews
CV information above last modified August 25, 2026